Hypersensitivity Pneumonitis Market size is poised to reach USD 2 Billion by the end of 2035, growing at a CAGR of 6% during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry size of hypersensitivity pneumonitis was USD 1 Billion. The reason behind the growth is impelled by the increasing prevalence of respiratory diseases across the globe. The third biggest cause of mortality is chronic respiratory conditions caused by risk factors including allergens, occupational dangers, and tobacco use. This has increased awareness regarding such conditions among people, leading to better treatment options for hypersensitivity pneumonitis as well. Each year, asthma accounts for more than 160 000 fatalities worldwide.
The development of non-invasive diagnostic procedures are believed to fuel the hypersensitivity pneumonitis market. Imaging and spirometry are non-invasive techniques used in diagnosis and the measurement of the lung's capacity to inhale and exhale air. For instance, HRCT is a noninvasive, precise diagnostic technology used for the proper diagnosis of chronic hypersensitivity pneumonitis.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~6% |
|
Base Year Market Size (2022) |
~ USD 1 Billion |
|
Forecast Year Market Size (2035) |
~ USD 2 Billion |
|
Regional Scope |
|
Growth Drivers
Challenges
Treatment (Immunosuppressive, Corticosteroids)
The corticosteroids segment is estimated to account for 60% share of the global hypersensitivity pneumonitis market in the coming years owing to the benefits provided by this treatment. Corticosteroids are considered in patients with severe lung function impairment as both low-dose oral corticosteroids provide adequate initial treatment of acute hypersensitivity pneumonitis. Corticosteroids improve survival and slow fibrotic progression in a matched cohort and the therapy may accelerate the initial recovery in persons with severe disease. For instance, corticosteroids such as prednisone usually 60 mg orally once a day for 1 to 2 weeks, are prescribed for severe symptoms or significant lung dysfunction.
End-User (Hospital, Online Pharmacy, Drug Stores, Retail Pharmacy)
Hypersensitivity pneumonitis market from the hospital segment is set to garner a notable share shortly on account of growing advancements in diagnostic techniques. Hospitals are equipped with advanced tools for diagnosis of various diseases including hypersensitivity pneumonitis. This may lead to more patients visiting hospitals for managing acute to severe cases of hypersensitivity pneumonitis.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
Treatment |
|
|
End-User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this Report
North American Market Forecast
Hypersensitivity pneumonitis market in North America is predicted to account for the largest share of 37% by 2035 impelled by the increasing spending in healthcare. This would allocate more resources to the healthcare which may improve the diagnostic capabilities and provide access to treatments for people with hypersensitivity pneumonitis.
According to estimates, Healthcare costs in the US are currently rising by over 1% faster than the GDP every year and by 2028 spending on healthcare in the United States will total more than USD 6 trillion.
European Market Statistics
The Europe hypersensitivity pneumonitis market is estimated to be the second largest, during the forecast timeframe led by growing healthcare awareness. Various campaigns and awareness programs are being conducted in the region which has led to an increase in public knowledge about the hypersensitivity pneumonitis disease. As a result, more and more people are being diagnosed with the disease.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: Increasing prevalence of respiratory diseases across the globe and the development of non-invasive diagnostic procedures are the major factors driving the growth of the market.
Ans: The market size of Hypersensitivity Pneumonitis is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023 – 2035.
Ans: The major players in the market are Svizera Healthcare Pvt. Ltd., Sanofi S.A., Novo Nordisk A/S, Astra Zeneca Plc., Eli lilly and Company, Bayer AG, Sun Pharmaceutical Industries Ltd., Novartis AG.
Ans: The corticosteroids segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Ans: The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?